|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Overall, SMURF1-mediated ubiquitination of ARHGAP26 may promote invasion and migration of ovarian cancer cells via the β-catenin pathway.
|
31004081 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Ectopic expression of CLDN18-ARHGAP26 promotes the migration and invasion capacities of DGC cells.
|
30361512 |
2018 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The circ-ARHGAP26 expression was elevated in HGC-27 (P < 0.001), AGS (P < 0.001), SGC-7901 (P < 0.01), BGC-823 (P < 0.05) and NCI-N87 (P < 0.05) GC cell lines compared to GSE-1 cells.
|
30719998 |
2019 |
|
Somatic mutation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Secondary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ARHGAP26 upregulation in A2780 cells also inhibited lung metastasis in vivo.
|
31004081 |
2019 |
|
RETINITIS PIGMENTOSA 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry analysis revealed that Myo1d, ARHGAP26, and RP1 were specifically expressed in the subendothelial region of constricted DAs; however, diffuse expression of these proteins was noted in the patent group.
|
25915513 |
2015 |
|
Psychotic symptom
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here, we report a newly diagnosed anti-Ca/ARHGAP26-IgG-positive patient who presented with recurrent psychotic symptoms but no cerebellar ataxia.
|
26298328 |
2015 |
|
Psychotic Disorders
|
0.300 |
Biomarker
|
group |
PSYGENET |
Here, we report a newly diagnosed anti-Ca/ARHGAP26-IgG-positive patient who presented with recurrent psychotic symptoms but no cerebellar ataxia.
|
26298328 |
2015 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer.
|
29961079 |
2018 |
|
Patent ductus arteriosus - persisting type
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ARHGAP26 messenger RNA and protein levels were decreased in patent DA tissue (both P ≤ 0.018).
|
25915513 |
2015 |
|
Patent ductus arteriosus
|
0.020 |
Biomarker
|
disease |
BEFREE |
ARHGAP26-knocked-down human DASMCs showed reduced proliferation and migration, which are both crucial to anatomic closure of DA.
|
30592323 |
2019 |
|
Patent ductus arteriosus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
ARHGAP26 messenger RNA and protein levels were decreased in patent DA tissue (both P ≤ 0.018).
|
25915513 |
2015 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Rho GTPase-activating protein 26 (ARHGAP26) is a negative regulator of the Rho family that converts the small GTP-binding protein RhoA (GTP-RhoA) to its inactive GDP-bound form and is a putative tumor suppressor gene associated with cell growth and migration.
|
31004081 |
2019 |
|
Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Furthermore, the cell-matrix Rho GTPase-encoding ARHGAP26 gene, and MAN1C1, a gene encoding a Golgi mannosidase involved in the maturation of procollagens, emerged as new candidate uterine leiomyoma genes affecting both risk and tumor size.
|
25455875 |
2015 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Consistent with the tumor suppressive role of claudins shown in mice, in humans, claudin-low breast cancer has been described as a distinct entity with a poor prognosis, and claudin-18-Rho GTPase activating protein 26 (CLDN18-ARHGAP26) fusion protein as a driver gene aberration in diffuse-type gastric cancer due to effects on RhoA.
|
31332482 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
GTPase regulator associated with focal adhesion kinase (GRAF), a putative tumor suppressor gene, was revealed with mutations and promoter methylation in AML and myelodysplastic syndrome.
|
21074269 |
2011 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Our data support a role for clathrin-independent endocytic machinery in balancing membrane tension, which clarifies the previously reported role of GRAF1 as a tumor suppressor.
|
28834752 |
2017 |
|
Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
The particular position of the human GRAF gene at 5q31 and the proposed antiproliferative and tumor suppressor properties of its avian homologue suggest that it also might be pathogenetically relevant for hematologic malignancies with deletions of 5q.
|
10908648 |
2000 |
|
Myelomonocytic leukemia
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Myeloid Leukemia, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the expression level of GRAF gene in those patients with myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML).
|
20704716 |
2010 |
|
Myelodysplastic Syndrome Acute Myeloid Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q.
|
10908648 |
2000 |
|
MYELODYSPLASTIC SYNDROME
|
0.330 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to investigate the expression level of GRAF gene in those patients with myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML).
|
20704716 |
2010 |
|
MYELODYSPLASTIC SYNDROME
|
0.330 |
CausalMutation
|
group |
CGI |
|
|
|